Humanized bispecific antibody (mPEG?×?HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.

ABSTRACT: BACKGROUND:Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG?×?HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. RESULT:We used a one-step formulation to rapidly modify the nanoprobes with mPEG?×?HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The ?HER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2++) but not MCF7/neo1 cells (HER2+/-). The ?HER2/Lipo-DiR and ?HER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2++). In in vivo imaging, ?HER2/Lipo-DiR and ?HER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. CONCLUSION:mPEG?×?HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging.

SUBMITTER: Cheng YA 

PROVIDER: S-EPMC7457265 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature